ID
33932
Descrição
Study ID: 102936 Clinical Study ID: HZA102936 Study Title:A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01209026 https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Allermist,Veramyst,Avamys; Veramyst,Avamys,Allermist Study Indication: Asthma The study consists of a screening, 4 treatment periods and a follow up. Treatment periods 1-4 are each 7 days long. Treatment period 1 Days 1-6 (TP1D-D6) Treatment period 1 Day 7 (TP1D7) Treatment period 2 Days 1-6 (TP2D1-D6) Treatment period 2 Day 7 (TP2D7) Treatment period 3 Days 1-6 (TP3D1-D6) Treatment period 3 Day 7 (TP3D7) Treatment period 4 Days 1-6 (TP4D1-D6) Treatment period 4 Day 7 (TP4D7) This document contains the Pharmacokinetic (PGx) research withdrawl of consent (PGx withdrawl) form. It has to be filled in for the end of study.
Link
https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026
Palavras-chave
Versões (3)
- 08/01/2019 08/01/2019 -
- 10/01/2019 10/01/2019 - Sarah Riepenhausen
- 10/01/2019 10/01/2019 - Sarah Riepenhausen
Titular dos direitos
GlaxoSmithKline
Transferido a
8 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Effect of inhaled fluticasone furoate/Vilanterol combination on electrocardiographic parameters in healthy subjects, NCT01209026
Pharmacokinetic (PGx) research withdrawl of consent (PGx withdrawl)
Descrição
C2347500 C1707492
Descrição
Withdrawl of consent for PGx
Tipo de dados
text
Alias
- UMLS CUI [1]
- C1707492
Descrição
day month year
Tipo de dados
date
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C0011008
Descrição
Request to sample destruction
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
- UMLS CUI [1,3]
- C1272683
Descrição
Screen failure is an optional choice. Please replace 'insert sample type' with the appropriate sample type as specified in the protocol.
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
- UMLS CUI [1,3]
- C1272683
- UMLS CUI [1,4]
- C0392360
Descrição
Other reason for request to sample destruction
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
- UMLS CUI [1,3]
- C1272683
- UMLS CUI [1,4]
- C0392360
- UMLS CUI [1,5]
- C0205394
Descrição
Design Notes
Alias
- UMLS CUI-1
- C0947611
Similar models
Pharmacokinetic (PGx) research withdrawl of consent (PGx withdrawl)
C0011008 (UMLS CUI [1,2])
C0178913 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0178913 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0392360 (UMLS CUI [1,4])
C0178913 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0392360 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])
C1948029 (UMLS CUI [1,2])
C0178913 (UMLS CUI [1,3])